ProCE Banner Activity

Phase II Trial of Ruxolitinib + Thalidomide in Patients With Myelofibrosis

Slideset Download
Conference Coverage
Combination therapy achieved objective clinical improvements in disease status, including durable hematologic responses.

Released: December 11, 2018

Expiration: December 10, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology